ストックスクリーナーアプリを入手
31.06
1.77%
0.54
Tango Therapeutics Inc (TNGX) 最新ニュース
Top Hyperliquid Strategies (PURR) Competitors 2026 - MarketBeat
Does Tango Therapeutics' (TNGX) Russell Growth Shift Reveal Its True Biotech Identity to Institutions? - simplywall.st
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
Tango Therapeutics president Crystal Adam sells $798,908 in stock By Investing.com - Investing.com South Africa
Form 4 Tango Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Tango Therapeutics president Crystal Adam sells $798,908 in stock - Investing.com
Tango Therapeutics (TNGX) R&D president exercises options and sells 27,000 shares - Stock Titan
Price to book forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Tango Therapeutics Rides a New Precision Oncology Trend in 2026 - Yahoo Finance
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026? - Yahoo Finance
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts - Yahoo Finance
TNGX Q1 2026 Earnings: Net Loss Slightly Misses Estimates as Pre-Revenue Biotech Advances PipelineHigh Growth Earnings - dars.gov.et
TNGX Maintained by Canaccord Genuity -- Price Target Raised to $46 - GuruFocus
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2500 Growth Benchmark - marketscreener.com
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2000 Growth Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000E Growth Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 3000E Index - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell Microcap Index - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 2500 Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Enterprise value to revenue forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Enterprise value to EBITDA forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Jefferies Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
TNGX Upgraded by Jefferies -- Price Target Raised to $60 - GuruFocus
Jefferies Upgrades Tango Therapeutics to Buy From Hold, Price Target Is $27 - Moomoo
Tango Therapeutics Inc (TNGX) Institutional Confidence - TradingKey
Tango Therapeutics, Inc. Actuals & Estimates (NASDAQ:TNGX) - TradingView
Enterprise value to EBIT forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Jefferies upgrades Tango Therapeutics stock rating on cancer trial data By Investing.com - Investing.com Nigeria
Jefferies Upgrades Tango Therapeutics(TNGX.US) to Buy Rating, Raises Target Price to $60 - Moomoo
Jefferies upgrades Tango Therapeutics stock rating on cancer trial data - Investing.com
TNGX Forecast — Price Target — Prediction for 2027 - TradingView
Why is Tango Therapeutics stock surging today? By Investing.com - Investing.com Nigeria
Price to sales forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Form 8K Tango Therapeutics Inc For: 23 June By Investing.com - Investing.com Australia
Form 4 Tango Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa
Director at Tango Therapeutics (TNGX) receives RSUs and stock options - Stock Titan
New Tango Therapeutics (TNGX) director Robert Azelby files initial Form 3 - Stock Titan
Robert Azelby appointed to Tango Therapeutics board, joins Compensation and NCG Committees - TradingView
Biotech veteran Robert Azelby joins Tango Therapeutics (TNGX) board as company advances vopimetostat - Stock Titan
Positive trial data lifts forecasts for Tango Therapeutics’ oncology program - S&P Global
Tango Therapeutics Appoints New Board Member - Intellectia AI
Tango Therapeutics Company Profile & Introduction - Moomoo
2.64%
大文字化:
|
ボリューム (24 時間):